Drugdiscovery >> Drugs >> News
5469
Views
Priority Review designation for Nexavar - drugdiscovery.com
Priority Review designation for Nexavar - drugdiscovery.com


FDA has granted Priority Review designation for the Bayer HealthCare’s and Onyx Pharmaceuticals’ oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
Read More >>


Tags: Nexavar, sorafenib, thyroid cancer, advanced, Bayer HealthCare, Onyx Pharmaceuticals, priority review designation, FDA - August 28, 2013
Related Articles
5025
Views
Priority Review for blood cancer treatment Ibrutinib Priority Review for blood cancer treatment Ibrutinib
The FDA is giving Priority Review to Pharmacyclics’ drug Ibrutinib as a treatment for previously treated cases of mantle cell lymphoma and chronic lymphocytic leukemia. Read More >>

Tags: priority review, Pharmacyclics, Ibrutinib, mantle cell lymphoma, chronic lymphocytic leukemia

3960
Views
Priority Review for Takeda's vedolizumab for the treatment of ulcerative colitis Priority Review for Takeda's vedolizumab for the treatment of ulcerative colitis
After a successful Phase 3 study of Takeda’s new investigational drug vedolizumab, FDA has granted Priority Review status for the drug for the treatment of adults with moderately to severely active Read More >>

Tags: vedolizumab, ulcerative colitis, Takeda, FDA, priority review

3661
Views
Priority Review for GSK’s cancer drug combo Priority Review for GSK’s cancer drug combo
GSK has been granted Priority Review designation by the FDA, for its supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) in the treatment of Read More >>

Tags: GSK, tafinlar, dabrafenib, mekinist,trametinib, metastatic melanoma, BRAF V600 mutation

1687
Views
Quo Vadis Drug Discovery? - a Book review Quo Vadis Drug Discovery? - a Book review
The Future of Drug Discovery: Who decides which diseases to treat? is an outstanding book, written by Tamas Bartfai and Graham V. Lees. According to the workers of pharmaceutical trade, it provides a Read More >>

Tags: drug discovery, book, review, future

5889
Views
A positive review of  Roche’s  Perjeta in early stage breast cancer A positive review of Roche’s Perjeta in early stage breast cancer
The FDA has issued a positive review of Perjeta and recommended accelerating approval. In mid-stage trials, women with early-stage breast cancer who received the drug had significantly fewer tumor Read More >>

Tags: Perjeta, Roche, breast cancer, early stage, FDA, review

5510
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

7917
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

16131
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

5579
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

6114
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013